NAD Metabolism in Acute Myeloid Leukaemia: Biological Rationale and Therapeutic Opportunities
Nutrients · 13.07.2026 · 18 (14) · 2295
DOI: 10.3390/nu18142295 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nutrients, online erschienen am 13.07.2026. Verfasst von Klaartje Somers und 2 weiteren Autor:innen. Beteiligte Einrichtung: Children's Cancer Institute, Minderoo Children's Comprehensive Cancer Centre, Sydney, NSW 2031, Australia. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, NAD. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Acute myeloid leukaemia (AML) exhibits profound metabolic plasticity that enables leukaemic cells to survive environmental stress, nutrient limitation, and therapeutic pressure, ultimately driving disease persistence and relapse. While genetic and epigenetic alterations have guided risk stratification and therapeutic development, accumulating evidence indicates that nutrient-dependent metabolic rewiring represents a critical and targetable vulnerability in AML. Nicotinamide adenine dinucleotide (NAD) is a central metabolic cofactor whose intracellular availability is tightly linked to dietary intake of its precursors, including tryptophan, niacin (vitamin B3), nicotinamide, and nicotinamide riboside. NAD supports redox balance, mitochondrial metabolism, DNA repair, and stress adaptation, processes that are particularly critical for leukaemic stem cell survival under therapeutic stress. Recent studies demonstrate that AML cells, including those resistant to venetoclax- and hypomethylating agent–based regimens, exhibit heightened dependence on the NAD salvage pathway mediated by nicotinamide phosphoribosyltransferase (NAMPT). Pharmacological inhibition of this pathway induces profound NAD depletion, mitochondrial dysfunction, and selective leukaemic cell death. In this review, we integrate nutritional biology with emerging translational evidence to examine NAD metabolism as a nutrient-regulated metabolic vulnerability in AML. We discuss dietary sources and systemic regulation of NAD, the role of NAD-dependent pathways in leukaemic persistence, the translational exploitation of NAD salvage dependency, and the emerging controversy surrounding NAD supplementation in cancer. Finally, we highlight key knowledge gaps and future directions at the interface of nutrition, metabolism, and therapy response in AML.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Children's Cancer Institute, Minderoo Children's Comprehensive Cancer Centre, Sydney, NSW 2031, Australia.
- School of Clinical Medicine, UNSW Medicine & Health, UNSW Sydney, Sydney, NSW 2052, Australia.
- Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC 3052, Australia.
- Department of Medical Biology, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, VIC 3010, Australia.
- Australian Centre for Blood Diseases, Monash University, Melbourne, VIC 3044, Australia.
ORCID-Profile: Klaartje Somers, Mawar Karsa, Donia M Moujalled
Zitieren
APA
Somers, K., Karsa, M., & Moujalled, D. M. (2026). NAD Metabolism in Acute Myeloid Leukaemia: Biological Rationale and Therapeutic Opportunities. Nutrients, 18(14), 2295. https://doi.org/10.3390/nu18142295
Vancouver
Somers K, Karsa M, Moujalled DM. NAD Metabolism in Acute Myeloid Leukaemia: Biological Rationale and Therapeutic Opportunities. Nutrients. 2026;18(14):2295. doi:10.3390/nu18142295
BibTeX
@article{Somers2026,
author = {Somers, Klaartje and Karsa, Mawar and Moujalled, Donia M},
title = {NAD Metabolism in Acute Myeloid Leukaemia: Biological Rationale and Therapeutic Opportunities},
journal = {Nutrients},
year = {2026},
volume = {18},
number = {14},
pages = {2295},
doi = {10.3390/nu18142295}
}
EUVIMED